Cytokine Profile of the Uterine Secretome After Therapeutic Endometrial Scratching
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 150
- 试验地点
- 4
- 主要终点
- Cytokine profile of the uterine secretome after therapeutic endometrial scratching
研究概览
简要总结
This study investigates the impact of endometrial scratching on endometrial secretion, when correlated to pregnancy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •IVF or ICSI patients with ≥1 previous implantation failure, despite transfer of a top quality embryo or blastocyst.
- •Antagonist treatment
- •FSH: 2-12 IU/L
- •BMI: 18-32
- •Regular menstrual cycle
- •Written consent
排除标准
- •Suspected intrauterine abnormalities Planned use of specialized media or AHA
结局指标
主要结局
Cytokine profile of the uterine secretome after therapeutic endometrial scratching
时间窗: Within 12 months
The secretome is analyzed using a Multiplex analysis with 45 cytokines, chemokines and growth factors from ProcartaPlex Immunoassay Kit, Affymetrix, eBioscience. The samples are normalized for total protein content using a Nanodrop spectrophometer, and the protein composition is further determined by sodium dodecyl sulphate-polyacrylamide gel electropheresis (SDS-PAGE).
Immunoassay Kit:
时间窗: Within 12 months
BDNF, EGF, Eotaxin, FGF-2, GMCSF, GRO-alpha, HGF, IFN alpha, IFN gamma, IL-1RA, IL-1alpha, IL-1 beta, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL17-A, IL-18, IL-21, IL-22, IL-23, IL-27, IL-31, IP-10, LIF, MCP-1, MIP-1 alpha, MIP-1 beta, NGF beta, RANTES, PDGF-BB, PÅIGF-1, SCF, SDF-1 alpha, TNF alpha, TNF beta, VEGF-A, VEGF-D
次要结局
未报告次要终点